<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406377</url>
  </required_header>
  <id_info>
    <org_study_id>DPO-203</org_study_id>
    <nct_id>NCT03406377</nct_id>
  </id_info>
  <brief_title>Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects</brief_title>
  <official_title>A Phase 2, Double-blind Dose Escalation Regimen of Once-Weekly OPK-88003 in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Ireland Global Holdings Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC)
      OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects
      with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise alone, or
      treated with a stable dose of metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a phase 2, double-blind dose escalation regimen of once-weekly
      OPK-88003 in subjects with T2DM. The trial consists of four phases: a screening/baseline
      phase (up to 2 weeks prior to first dose), a 30-week treatment period consisting of a dose
      escalation phase (8 weeks) and a target dose phase (22 weeks), and a follow-up period (4
      weeks). Subjects will be randomly assigned to volume-matched OPK-88003 or placebo
      administered QW.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c in subjects with type 2 DM</measure>
    <time_frame>From baseline to 30 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean percent (%) body weight change</measure>
    <time_frame>From baseline to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent (%) of subjects with 5% or greater body weight loss.</measure>
    <time_frame>30 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of fasting plasma glucose (FPG).</measure>
    <time_frame>30 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OPK-88003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPK-88003</intervention_name>
    <description>OPK-88003 subcutaneous injection</description>
    <arm_group_label>OPK-88003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 18 to 80 years with T2DM treated with diet and exercise alone or on
             a stable dose of metformin (≥ 1000 mg/day),

          -  BMI ≥27 and ≤45 kg/m2

          -  HbA1c ≥7.0% and ≤10.5% at screening

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Previous treatment with incretin mimetic drugs

          -  Have used insulin for diabetic control for more than 6 consecutive days within the
             prior year

          -  Have had two or more emergency room visits or hospitalizations due to poor glucose
             control within the prior 6 months

          -  Have a history of acute or chronic pancreatitis or elevation in serum lipase/amylase
             (&gt;2 x ULN).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiao Kuang</last_name>
    <phone>+1-416-260-7770</phone>
    <email>jkuang@transitiontherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Hsin-Wei Hsia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Pablo Frias</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Lasseter, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

